--- title: Extranodal NK/T-Cell Lymphoma (ENKTCL) url: "https://www.yyhmedical.com/en/guide/blood/extranodal-nk-t-cell-lymphoma" type: MedicalWebPage inLanguage: en-US --- # Extranodal NK/T-Cell Lymphoma (ENKTCL) > Extranodal NK/T-cell lymphoma (ENKTCL) is a rare and aggressive type of non-Hodgkin lymphoma that is strongly associated with Epstein-Barr virus (EBV). It most commonly develops in the nasal cavity and upper aerodigestive tract. ## Overview Extranodal NK/T-cell lymphoma (ENKTCL) is a rare and aggressive type of non-Hodgkin lymphoma. Most cases arise from natural killer (NK) cells, while a smaller proportion arise from cytotoxic T cells. ENKTCL shows distinct geographic patterns and is more common in parts of Asia and Central and South America. It most often develops in the **nasal cavity, nasopharynx, paranasal sinuses, and other areas of the upper aerodigestive tract**. Although ENKTCL is an aggressive lymphoma, advances in radiation therapy, asparaginase-based treatment, and newer therapies have improved treatment options. Disease stage, tumor burden, EBV DNA levels, and response to treatment are among the factors that can influence treatment decisions and outcomes. ## Causes The exact cause of ENKTCL is not fully understood, but the disease is **strongly associated with Epstein-Barr virus (EBV)**. EBV is found in the tumor cells of ENKTCL and is an important biological feature of the disease. However, having an EBV infection does not mean that someone will develop ENKTCL. EBV infection is very common, while ENKTCL remains rare. Genetic and molecular changes in lymphoma cells, as well as changes in the immune microenvironment, are also involved in the development of ENKTCL and continue to be studied. ## Signs and Symptoms Symptoms of ENKTCL depend on where the lymphoma develops and how far the disease has spread. When ENKTCL involves the nasal cavity or upper aerodigestive tract, symptoms may include: Persistent nasal congestion, Nosebleeds, Swelling in the nose or nasopharynx, Facial swelling or pain, Sores or ulcers in the nose, mouth, or palate that do not heal, Throat discomfort or difficulty swallowing. Some people may also develop **B symptoms**, including: Unexplained fever, Drenching night sweats, Unexplained weight loss. ENKTCL can also develop outside the nasal area, including the skin, gastrointestinal tract, or testes. Symptoms vary depending on the part of the body involved. ## Diagnosis If ENKTCL is suspected because of symptoms such as persistent nasal congestion, a mass in the nasal cavity or nasopharynx, or a nonhealing ulcer, a **tissue biopsy** is usually needed to confirm the diagnosis. Imaging and EBV-related testing can then help evaluate the extent of the disease. ### **Biopsy** A tissue biopsy is essential for diagnosing ENKTCL. A tissue sample from the affected area is examined by a pathologist. Immunohistochemistry and EBV-related testing are used to help identify the characteristics of the lymphoma cells. ENKTCL may show features such as angiocentric growth, blood vessel destruction, and tissue necrosis. Because some lesions contain extensive necrosis, an additional biopsy may occasionally be needed to obtain enough viable tissue for diagnosis. ### **EBV Testing** Testing for EBV in tumor tissue is an important part of the pathological diagnosis of ENKTCL. **EBV DNA levels** in peripheral blood can also be measured using quantitative PCR. EBV DNA can be assessed before treatment and monitored over time to help evaluate treatment response and changes in the disease. ### **PET/CT and Other Imaging Tests** PET/CT can help show where lymphoma is located throughout the body and is an important tool for staging ENKTCL and assessing treatment response. CT or MRI may also be used to evaluate disease involving the nasal cavity, sinuses, face, or nearby structures and can provide additional information for treatment planning, particularly radiation therapy. ### **Blood and Other Tests** Blood tests can measure red blood cells, white blood cells, and platelets and assess liver and kidney function, lactate dehydrogenase (LDH), and other markers. Additional tests may be performed depending on the location and extent of the disease. ## Treatment Treatment for ENKTCL depends on several factors, including **disease stage, tumor location and burden, overall health, and response to treatment**. Treatment strategies differ between localized and advanced disease. Radiation therapy and **asparaginase-based systemic therapy** are important components of ENKTCL treatment. Traditional CHOP or CHOP-like chemotherapy is generally not used as standard treatment for ENKTCL. ### **Treatment for Localized Disease** For localized ENKTCL, **radiation therapy is a central part of treatment**. For patients who are able to receive systemic therapy, radiation is often combined with an asparaginase-containing treatment regimen. Radiation and systemic therapy may be given concurrently, sequentially, or in other combinations depending on the disease and the individual patient. Radiation therapy alone may be considered for selected patients with low-burden stage I disease or for those who are unable to tolerate systemic therapy. ### **Treatment for Advanced Disease** For advanced ENKTCL, treatment is generally based on **multi-drug regimens that include asparaginase**. Different regimens containing pegaspargase or L-asparaginase may be considered depending on the characteristics of the disease and the patient’s overall health. Radiation therapy may also be used in selected cases depending on disease location and treatment response. Newer approaches, including **PD-1/PD-L1–directed immunotherapy**, are also being studied and used in ENKTCL, particularly for relapsed or refractory disease. ### **Relapsed or Refractory ENKTCL** Some patients may experience a relapse after treatment or may not respond adequately to initial therapy. For relapsed or refractory ENKTCL, treatment decisions depend on factors such as previous therapies, the timing and location of relapse, EBV DNA levels, and overall health. Treatment options may include other asparaginase-based regimens, immunotherapy, hematopoietic stem cell transplantation, or clinical trials. ### **Hematopoietic Stem Cell Transplantation (HSCT)** Hematopoietic stem cell transplantation is not needed for everyone with ENKTCL and is **not routinely used as first-line treatment for localized disease**. For selected patients with advanced, high-risk, or relapsed/refractory ENKTCL who achieve a good response to treatment and are eligible for transplantation, HSCT may be considered. Depending on disease status, response to previous treatment, overall health, and donor availability, either **autologous or allogeneic HSCT** may be considered. The decision about whether to proceed with transplantation and which type to use requires individualized assessment. ### **Clinical Trials** Because ENKTCL is rare, treatment continues to evolve. Clinical trials are studying new immunotherapies, targeted therapies, and treatment combinations. For people with advanced, relapsed, or refractory disease, discussing available clinical trials with the healthcare team may help identify additional treatment options. ## Content attribution (YMYL) - Author: - Medically reviewed by: - Last reviewed: - First published: > --- Original (HTML):https://www.yyhmedical.com/en/guide/blood/extranodal-nk-t-cell-lymphoma This is a clean Markdown mirror for large language models; the original page is authoritative.